180 related articles for article (PubMed ID: 27995250)
1. Discovery of new dual binding TNKS inhibitors of Wnt signaling inhibition by pharmacophore modeling, molecular docking and bioassay.
Pu Y; Zhang S; Chang Z; Zhang Y; Wang D; Zhang L; Li Y; Zuo Z
Mol Biosyst; 2017 Jan; 13(2):363-370. PubMed ID: 27995250
[TBL] [Abstract][Full Text] [Related]
2.
Liu J; Feng K; Ren Y
J Biomol Struct Dyn; 2019 Sep; 37(14):3803-3821. PubMed ID: 30261821
[TBL] [Abstract][Full Text] [Related]
3. Molecular insights on TNKS1/TNKS2 and inhibitor-IWR1 interactions.
Kirubakaran P; Kothandan G; Cho SJ; Muthusamy K
Mol Biosyst; 2014 Feb; 10(2):281-93. PubMed ID: 24291818
[TBL] [Abstract][Full Text] [Related]
4. Sighting of tankyrase inhibitors by structure- and ligand-based screening and in vitro approach.
Kirubakaran P; Arunkumar P; Premkumar K; Muthusamy K
Mol Biosyst; 2014 Oct; 10(10):2699-712. PubMed ID: 25091558
[TBL] [Abstract][Full Text] [Related]
5. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
[TBL] [Abstract][Full Text] [Related]
6. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
7. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
[TBL] [Abstract][Full Text] [Related]
8.
Loganathan L; Muthusamy K; Jayaraj JM; Kajamaideen A; Balthasar JJ
J Biomol Struct Dyn; 2019 Sep; 37(14):3637-3648. PubMed ID: 30204055
[TBL] [Abstract][Full Text] [Related]
9. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
10. The discovery of new acetylcholinesterase inhibitors derived from pharmacophore modeling, virtual screening, docking simulation and bioassays.
Zhang Y; Zhang S; Xu G; Yan H; Pu Y; Zuo Z
Mol Biosyst; 2016 Nov; 12(12):3734-3742. PubMed ID: 27801451
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tankyrase by a novel small molecule significantly attenuates prostate cancer cell proliferation.
Cheng H; Li X; Wang C; Chen Y; Li S; Tan J; Tan B; He Y
Cancer Lett; 2019 Feb; 443():80-90. PubMed ID: 30472184
[TBL] [Abstract][Full Text] [Related]
12. 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.
Nkizinkiko Y; Desantis J; Koivunen J; Haikarainen T; Murthy S; Sancineto L; Massari S; Ianni F; Obaji E; Loza MI; Pihlajaniemi T; Brea J; Tabarrini O; Lehtiö L
Sci Rep; 2018 Jan; 8(1):1680. PubMed ID: 29374194
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.
Nathubhai A; Haikarainen T; Hayward PC; Muñoz-Descalzo S; Thompson AS; Lloyd MD; Lehtiö L; Threadgill MD
Eur J Med Chem; 2016 Aug; 118():316-27. PubMed ID: 27163581
[TBL] [Abstract][Full Text] [Related]
15. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H
Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443
[TBL] [Abstract][Full Text] [Related]
16. Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity.
Nathubhai A; Haikarainen T; Koivunen J; Murthy S; Koumanov F; Lloyd MD; Holman GD; Pihlajaniemi T; Tosh D; Lehtiö L; Threadgill MD
J Med Chem; 2017 Jan; 60(2):814-820. PubMed ID: 27983846
[TBL] [Abstract][Full Text] [Related]
17. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
[TBL] [Abstract][Full Text] [Related]
18. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.
Narwal M; Koivunen J; Haikarainen T; Obaji E; Legala OE; Venkannagari H; Joensuu P; Pihlajaniemi T; Lehtiö L
J Med Chem; 2013 Oct; 56(20):7880-9. PubMed ID: 24116873
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel Tankyrase Inhibitors through Molecular Docking-Based Virtual Screening and Molecular Dynamics Simulation Studies.
Berishvili VP; Kuimov AN; Voronkov AE; Radchenko EV; Kumar P; Choonara YE; Pillay V; Kamal A; Palyulin VA
Molecules; 2020 Jul; 25(14):. PubMed ID: 32664504
[TBL] [Abstract][Full Text] [Related]
20. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
